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BACKGROUND: Symptomatic intracranial atherosclerotic disease (ICAD) is an important
cause of stroke. Although the high periprocedural risk of intracranial stenting from recent
randomized studies has dampened enthusiasm for such interventions, submaximal angio-
plasty without stenting may represent a safer endovascular treatment option.
OBJECTIVE: To examine the periprocedural and long-term risks associated with
submaximal angioplasty for ICAD based on the available literature.
METHODS: All English language studies of intracranial angioplasty for ICAD were
screened. Inclusion criteria were as follows: ≥ 5 patients, intervention with submaximal
angioplasty alone, and identifiable periprocedural (30-d) outcomes. Analysis was co-
nducted to identify the following: 1) periprocedural risk of any stroke (ischemic or hemorrh-
agic) or death, and 2) stroke in the territory of the target vessel and fatal stroke beyond 30d.
Mixed effects logistic regression was used to summarize event rates. Funnel plot and rank
correlation tests were employed to detect publication bias. The relative risk of periproce-
dural events from anterior vs posterior circulation disease interventionwas also examined.
RESULTS: A total of 9 studies with 408 interventions in 395 patients met inclusion criteria.
Six of these studies included 113 posterior circulation interventions. The estimated pooled
rate for 30-d stroke or death following submaximal angioplasty was 4.9% (95% CI: 3.2%-
7.5%), whereas the estimated pooled rate beyond 30 dwas 3.7% (95% CI: 2.2%-6.0%). There
was no statistical difference in estimated pooled rate for 30-d stroke or death between
patientswith anterior (4.8%, 95%CI: 2.8%-7.9%) vsposterior (5.3%, 95%CI: 2.4%-11.3%) circu-
lation disease (P > .99).
CONCLUSION: Submaximal angioplasty represents a potentially promising intervention
for symptomatic ICAD.
KEYWORDS: Angioplasty, Blood flow, Hypoperfusion, Intracranial atherosclerotic disease, Stroke, Submaximal
angioplasty
Neurosurgery 86:755–762, 2020 DOI:10.1093/neuros/nyz337 www.neurosurgery-online.com
I ntracranial atherosclerotic disease (ICAD)is estimated to account for 8% to 10%of all ischemic strokes1 and carries a risk
of recurrent stroke of approximately 15% per
year without treatment.2 Stroke from ICAD can
be attributed to several mechanisms, including
hypoperfusion, thromboembolism, and small-
ABBREVIATIONS: CI, confidence interval; COSS, Carotid Occlusion Surgery Study; ICAD, intracranial atheroscle-
rotic disease; LR, likelihood ratio; QMRA, quantitative magnetic resonance angiography; SAMMPRIS, Stenting
vs Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis; VERiTAS, Verte-
brobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke
Neurosurgery Speaks! Audio abstracts available for this article at www.neurosurgery-online.com.
Supplemental digital content is available for this article at www.neurosurgery-online.com.
vessel occlusive disease.3-5 Treatment strategies
for stroke due to hemodynamic compromise aim
to augment blood flow to ischemic distal terri-
tories.6,7 Although endovascular angioplasty and
stenting of symptomatic intracranial atheroscle-
rotic lesions once appeared an attractive method
for flow augmentation, the Stenting vs Aggressive
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Medical Management for Preventing Recurrent Stroke in
Intracranial Stenosis (SAMMPRIS) study demonstrated the
periprocedural (30-d) stroke or death rate of endovascular
intervention to be significantly higher (14.7%) than aggressive
medical management (5.8%),8 eclipsing any potential long-term
benefit of the treatment. Despite aggressive medical management,
however, certain patients remain at high-risk for stroke, partic-
ularly patients with evidence of hemodynamic compromise.9,10
Submaximal angioplasty without stenting may be a safer endovas-
cular option for these high-risk patients in whom aggressive
medical management is insufficient. We sought to examine the
periprocedural and long-term risks associated with submaximal




PubMed was searched with the key words “intracranial” and “angio-
plasty” to identify studies published in English between January 1995
and October 2018. Reference lists of studies considered for inclusion
were also hand-searched for additional studies not captured in the
original PubMed search. Studies were considered for inclusion if they
reported on angioplasty for ICAD, and those that passed the screening
stage were obtained in full text and further evaluated by predetermined
inclusion and exclusion criteria. The systematic review of the literature
was conducted according to the Preferred Reporting Items for Systematic
reviews and Meta-Analysis (PRISMA) statement.
Study Selection Criteria
Studies were included if they met the following criteria: 1) ≥ 5
patients; 2) specification of submaximal angioplasty, with an accompa-
nying detailed description; 3) intervention with submaximal angioplasty
alone (ie, without stenting) for symptomatic ICADwith≥ 50% stenosis;
and 4) delineation of periprocedural (30-d) outcomes, as related to stroke
or death. To qualify as “submaximal,” the angioplasty balloon had to be
undersized by at least 0.5 mm or sized to approximately 50% to 80% of
the normal vessel diameter. Studies reporting on angioplasty for asymp-
tomatic ICAD or ICAD-related emergent large vessel occlusions were
excluded. There were no instances of multiple series reporting on the
same cohort, to the best of our knowledge.
OutcomeMeasures
The primary outcome assessed in this meta-analysis was peripro-
cedural stroke (ischemic or hemorrhagic) or death in patients who
underwent submaximal angioplasty for symptomatic ICAD. Additional
outcome measures included stroke in the territory of the target vessel
and fatal stroke beyond 30 d, minor procedural or periprocedural adverse
events, technical success, and restenosis.
Statistical Analysis
Mixed effects logistic regression was used to summarize event rates.11
The likelihood ratio (LR) test and I2 statistics were employed to test
heterogeneity. Funnel plots and rank correlation tests were performed
to detect publication bias. Subgroup analysis was performed to examine
the anterior and posterior circulations separately. To examine the relative
risk of events in posterior vs anterior circulation, Q and I2 statistics
were used to assess heterogeneity, and random effects models using the
DerSimonian and Laird11 estimator with Knapp andHartung12 standard
error adjustments to summarize the effect sizes. A permutation test was
implemented to test if the pooled relative risk differed from 1.0. Funnel
plots and Egger tests were performed to detect publication bias (Figures,
Supplemental Digital Content 1-4).13 For all meta-analyses, additional
sensitivities for comparing modeling with and without adjusting for
publication year and with and without random effect or outliers were
also conducted, as appropriate. All analyses were conducted in R (version
3.4.1; R Core Team, Vienna, Austria) using the “metafor” package.14 and
P < .05 was considered statistically significant.
RESULTS
Literature Search
The initial literature search yielded 2084 articles. The titles
and abstracts of these were examined, and 1927 were excluded
for irrelevance. Of the remaining 157 articles, 140 were excluded
because of small sample size and/or inclusion of nonsubmaximal
angioplasty or stenting procedures. Eight of the remaining 17
studies were further excluded because of a nonspecific description
of the submaximal angioplasty procedure employed. Nine studies
were included in the final meta-analysis. The PRISMA flow
diagram is provided (Figure 1).15-23
Study and Patient Characteristics
A total of 395 patients, 252 (63.8%) of whom were male, with
408 interventions from 9 studies met inclusion criteria (Table).
Six of these studies included 113 posterior circulation interven-
tions.15-18,21,23 Across all studies, the mean age of patients at the
time of intervention ranged from 53 to 65.7 yr. All submaximal
angioplasty procedures were for symptomatic ICAD, and none
were part of a mechanical thrombectomy intervention for an
emergent large vessel occlusion. In all studies, patients were
maintained on antiplatelet agents before and after submaximal
angioplasty. The most common regimen, reported in 6 (66.7%)
studies, included aspirin 325 mg daily and clopidogrel 75 mg
daily, although variation did exist within and among the studies.
Periprocedural and Long-TermOutcomes
With respect to periprocedural outcomes, heterogeneity among
the studies was not detected (nonsignificant LR test [P = .68]
and I2 = 0). Funnel plot analysis (Figure, Supplemental Digital
Content 1) and a nonsignificant correlation test (P = .36)
suggested the lack of significant publication bias. The estimated
pooled periprocedural event rate was 4.9% (95%CI: 3.2%-7.5%)
(Figure 2). Modeling with and without adjustment for publi-
cation year showed no statistical difference.
Subgroup analysis demonstrated a periprocedural event rate
of a 4.8% (95% CI: 2.8%-7.9%) (Figure 3A) for the anterior
circulation and 5.3% (95% CI: 2.4%-11.3%) in the posterior
circulation (Figure 3B). Across all studies, heterogeneity was not
detected (anterior, P = .35; posterior, P = .57), and publication
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FIGURE 1. PRISMA flow diagram.
bias was not observed (anterior, P = .60; posterior, P = .47)
(Figures, Supplemental Digital Content 2 and 3). The relative
risk for posterior vs anterior circulation periprocedural events was
1.0 (95%CI: 0.3-3.9; P= 1.0), indicating no statistical difference
between the 2 subgroups. The sensitivity analyses showed no
difference between models with and without adjustment for
publication year, or with and without random effects. A potential
outlier was identified in this analysis,17 but the relative risk
remained statistically consistent with 1.0 even after removing it
from the analysis.
Regarding stroke in the territory of the target vessel and fatal
stroke beyond 30 d, the estimated pooled event rate was 3.7%
(95% CI: 2.2%-6.0%). Across all studies, heterogeneity was
not detected (P = .48), and publication bias was not observed
(P = .61) (Figure, Supplemental Digital Content 4).
Other Outcomes
Minor procedural or periprocedural adverse events were
detailed in 6 studies comprising 289 patients, and included 27
(9.3%) arterial dissections, 11 (3.8%) transient ischemic attacks,
and 1 (0.3%) thromboembolic event, which required no further
intervention.16-19,21,22
In general, technical success was defined as a residual stenosis
of the parent vessel of ≤ 50% after angioplasty. However, other
studies held a broader definition of success, with “even a mild
degree of improvement in luminal stenosis”15 or patency of
the lesion without the need for stenting23 considered successful
results. As reported in 6 studies, technical success was achieved in
265 (96.4%) of 275 cases.17,19-23
In 6 studies reporting on 255 treated lesions, there were 47
(18.4%) cases of restenosis (stenosis ≥ 50%), of which only
7 (2.7%) were symptomatic.15,18-20,22,23 The mean time to
restenosis was not uniformly reported.
DISCUSSION
Key Results
Our meta-analysis of 9 studies comprising 395 patients with
408 symptomatic intracranial atherosclerotic lesions demon-
strated low periprocedural (4.9%) and long-term (3.7%) stroke
or death rates with a high technical success rate (96.4%) following
submaximal angioplasty. These results suggest that the periproce-
dural event rate of submaximal angioplasty compares favorably to
the stenting (14.7%) and medical (5.8%) arms of SAMMPRIS,8
the stenting (24.1%) and medical (9.4%) arms of the Vitesse
Intracranial Stent Study for Ischemic Stroke Therapy trial,24 and
the United States Wingspan Registry (15.7%).25 Among lesions
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FIGURE 2. Forest plot for periprocedural (30-d) event rates.
with follow-up, the analysis also showed that although 18.4% of
patients developed restenosis of the treated lesion, only a small
minority, 2.7%, experienced recurrent symptoms.
Interpretation
Previously published retrospective series comparing primary
intracranial nonsubmaximal angioplasty to stenting have demon-
strated lower rates of restenosis for stenting, and no difference
in stroke- and/or death-free survival.26-28 The more favorable
outcomes observed with submaximal angioplasty in the current
meta-analysis are likely due to several factors. From a hemody-
namic standpoint, Pouseuille’s law dictates that the volumetric
rate of blood flow is directly proportional to the radius of
the blood vessel to the fourth power. As a result, even an
improvement from 70% to 50% stenosis following angioplasty
amounts to an increase in blood flow by a factor of 7.7.29
This incremental increase in flow, in concert with an already
existent collateral circulation, is likely sufficient to meet the
metabolic demands of the ischemic territory distal to the occlusive
lesion.30 A partial return of blood flow and volume may also
be preferred to complete revascularization, especially in a circu-
lation with impaired autoregulatory mechanisms, as a sudden
robust augmentation in flow may lead to hyperperfusion with
resultant seizure activity or intracranial hemorrhage.31 From a
technical standpoint, submaximal angioplasty may be safer than
angioplasty plus stenting because of reduced manipulation and
disruption of friable atherosclerotic lesions. Angioplasty plus
stenting necessitates crossing the lesion with a microwire and 2
devices, whereas angioplasty alone requires only a single crossing.
Stents are bulky compared to small angioplasty balloons, and
the simple act of crossing the stenosis may dislodge athero-
matous fragments. It has also been postulated that stenting can
lead to local small-vessel occlusion. When deployed, the stent
exerts a strong radial force on the atherosclerotic plaque and may
push atheroma into the origins of adjacent perforator arteries.
In addition, aggressive angioplasty and stenting can cause local
arterial dissection, which can precipitate vessel rupture, occlusion,
or thromboembolic complications.18,32 Submaximal angioplasty
aims to restore blood flow to ischemic brain regions through
partial vessel recanalization and to minimize the aforementioned
risks associated with stenting procedures.
Despite the promising results from this meta-analysis, data
from large-scale randomized surgical and endovascular studies
support aggressive medical management as first-line treatment for
symptomatic ICAD. However, although antiplatelet and statin
medications may stabilize fragile atherosclerotic plaques and
reduce stroke from thromboembolism or branch atheromatous
disease, it is not clear that these medications reduce stroke specif-
ically because of hypoperfusion.5 Hemodynamic insufficiency is
an independent cause of stroke, and the low-flow state distal to
the intracranial stenosis also predisposes to small-vessel thrombus
formation and prevents clearance of emboli that originate from
the culprit atherosclerotic lesion, both of which compound the
risk of stroke in patients with hypoperfusion.10,33 Therefore, even
with aggressive medical treatment, there is a subset of patients
with symptomatic hemodynamic compromise who would likely
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FIGURE3. A, Forest plot for periprocedural (30-d) event rates from anterior circulation disease interventions.B, Forest plot for periprocedural
(30-d) event rates from posterior circulation disease interventions.
benefit from more aggressive intervention. Of prime impor-
tance, therefore, is accurate identification of these highest-risk
patients. The Carotid Occlusion Surgery Study (COSS) posited
that patients with symptomatic internal carotid artery occlusion
and an increased oxygen extraction fraction as measured by
positron emission tomography are at greatest risk for stroke and,
therefore, most likely to benefit from surgical revascularization.7
Thus, COSS randomized high-risk, flow-compromised patients
to extracranial-intracranial bypass, aimed at restoring flow, vs best
medical therapy. Although COSS was halted early and failed to
show a benefit to bypass, this was primarily related to excess
periprocedural risk that abrogated the beneficial impacts of the
surgery. In fact, the study demonstrated that stroke risk after the
periprocedural period was significantly reduced, and that oxygen
extraction fraction (the marker of flow compromise) was signifi-
cantly improved following flow restoration surgery.
Although the importance of intracranial hemodynamic
compromise as a stroke risk factor has been well established
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in the carotid circulation,3,34 its role has recently also been
demonstrated in the posterior circulation. Quantitative magnetic
resonance angiography (QMRA) is a noninvasive method of
assessing regional blood flow in the posterior circulation,35
and the Vertebrobasilar Flow Evaluation and Risk of Transient
Ischemic Attack and Stroke (VERiTAS) study demonstrated
that patients with compromised flow distal to vertebrobasilar
atherosclerotic lesions are at an increased risk of stroke.10,29 In
VERiTAS, during the 23 mo of median follow-up, recurrent
vertebrobasilar territory stroke occurred in 28% of patients with
low distal flow compared with only 9% of patients with normal
distal flow.10 Revascularization procedures for posterior circu-
lation hemodynamic compromise, however, are considered partic-
ularly high-risk. In fact, in SAMMPRIS, 15.4% of patients
with vertebral or basilar artery ICAD developed periprocedural
ischemic events after endovascular intervention, compared with
only 6.2% of patients with disease localized to the internal carotid
or middle cerebral arteries.36 In our meta-analysis, however,
despite a relatively wide CI, the periprocedural event rate did
not differ significantly between cases of anterior (4.8%) vs
posterior (5.3%) circulation disease. This may suggest that even
in the perforator-rich region of the basilar artery, submaximal
angioplasty is a potentially viable option for patients suffering
from disabling posterior circulation ischemia.37 Ultimately, even
posterior circulation patients identified as flow-compromised
using QMRA may benefit from procedures such as intracranial
submaximal angioplasty. Based on a Markov-modeling, in which
data from the VERiTAS cohort and available data on submaximal
angioplasty were integrated, the usage of QMRA to select patients
with symptomatic vertebrobasilar stenosis for submaximal angio-
plasty would be cost effective.38
Limitations and Generalizability
This study is subject to several limitations. The majority of
studies included in our analysis were retrospective in nature and
had small sample sizes, which may have introduced selection bias.
Aside from a gross comparison of anterior vs posterior circulation
disease event rates, our analysis did not include an evaluation or
assessment of submaximal angioplasty by specific lesion location
nor did it account for differential degrees of pre- and postinter-
vention stenosis. Additionally, the particular technique by which
submaximal angioplasty was performed21 was not standardized
across the studies and may have differed among the studies
included in the final meta-analysis. Although we did not find
evidence of statistical heterogeneity or publication bias, we cannot
exclude the possibility that our test statistics were underpowered
to detect these parameters because of the small number of studies
and the limitation of the available statistical approaches.
CONCLUSION
Submaximal angioplasty represents a potentially promising
therapeutic intervention for patients with hemodynamic
compromise from symptomatic ICAD. The rate of peripro-
cedural stroke or death (4.9%) compares favorably to the medical
arm of SAMMPRIS (5.8%), and the event rate of 3.7% beyond
30 d may suggest a sustained clinical benefit to submaximal
angioplasty over time. Although medical management remains
the first-line treatment for symptomatic ICAD, these results
support the need to examine prospectively the safety and
feasibility of submaximal angioplasty in selected high-risk,
flow-compromised patients with either anterior or posterior
circulation atherosclerotic disease.
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